MEDIVIR AB – YEAR END REPORT, JANUARY – DECEMBER 2018
Two new projects into clinicOctober – DecemberSignificant events during the quarter · The first patient was dosed in the phase II study with birinapant and Keytruda® as combination therapy in colorectal cancer. · The first patient with advanced cancer in the liver was dosed with the company's drug candidate MIV-818 in a phase Ia study. · MIV-828 was selected as a candidate drug for the treatment of acute myeloid leukemia (AML) and other forms of blood cancer. · Dr Uli Hacksell was appointed new CEO of Medivir. · A reorganization, with the aim of focusing the internal